AbbVie annual net profit margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Net Profit Margin Growth & History (ABBV)
AbbVie's net profit margin was 6.91% for fiscal 2025.
View full AbbVie company overviewAbbVie annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 6.91% | −0.68 pp |
| 2024 | 2024-12-31 | 7.59% | −1.36 pp |
| 2023 | 2023-12-31 | 8.95% | −11.44 pp |
| 2022 | 2022-12-31 | 20.39% | −0.15 pp |
| 2021 | 2021-12-31 | 20.54% | +10.46 pp |
| 2020 | 2020-12-31 | 10.08% | −13.62 pp |
| 2019 | 2019-12-31 | 23.69% | +6.33 pp |
| 2018 | 2018-12-31 | 17.36% | −1.45 pp |
| 2017 | 2017-12-31 | 18.82% | −4.40 pp |
| 2016 | 2016-12-31 | 23.22% | +0.72 pp |
| 2015 | 2015-12-31 | 22.50% | +13.62 pp |
| 2014 | 2014-12-31 | 8.89% | — |
AbbVie quarterly net profit margin
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.27% | +15.18 pp |
| Q1 2026 | 2026-03-31 | 4.63% | −5.01 pp |
| Q4 2025 | 2025-12-31 | 10.93% | +11.07 pp |
| Q3 2025 | 2025-09-30 | 1.18% | −9.62 pp |
| Q2 2025 | 2025-06-30 | 6.08% | −3.39 pp |
| Q1 2025 | 2025-03-31 | 9.64% | −1.48 pp |
| Q4 2024 | 2024-12-31 | −0.15% | −5.89 pp |
| Q3 2024 | 2024-09-30 | 10.80% | −1.97 pp |
| Q2 2024 | 2024-06-30 | 9.47% | −5.12 pp |
| Q1 2024 | 2024-03-31 | 11.12% | +9.17 pp |
| Q4 2023 | 2023-12-31 | 5.75% | −10.61 pp |
| Q3 2023 | 2023-09-30 | 12.77% | −13.89 pp |
| Q2 2023 | 2023-06-30 | 14.60% | +8.26 pp |
| Q1 2023 | 2023-03-31 | 1.96% | −31.21 pp |
| Q4 2022 | 2022-12-31 | 16.35% | −10.81 pp |
| Q3 2022 | 2022-09-30 | 26.66% | +4.50 pp |
| Q2 2022 | 2022-06-30 | 6.34% | +0.85 pp |
| Q1 2022 | 2022-03-31 | 33.17% | +5.86 pp |
| Q4 2021 | 2021-12-31 | 27.17% | +26.91 pp |
| Q3 2021 | 2021-09-30 | 22.17% | +4.28 pp |
| Q2 2021 | 2021-06-30 | 5.49% | +12.57 pp |
| Q1 2021 | 2021-03-31 | 27.31% | −7.61 pp |
| Q4 2020 | 2020-12-31 | 0.26% | −31.92 pp |
| Q3 2020 | 2020-09-30 | 17.89% | −4.33 pp |
| Q2 2020 | 2020-06-30 | −7.08% | −16.06 pp |
| Q1 2020 | 2020-03-31 | 34.92% | +3.55 pp |
| Q4 2019 | 2019-12-31 | 32.18% | +54.17 pp |
| Q3 2019 | 2019-09-30 | 22.22% | −11.13 pp |
| Q2 2019 | 2019-06-30 | 8.98% | −14.98 pp |
| Q1 2019 | 2019-03-31 | 31.37% | −3.70 pp |
| Q4 2018 | 2018-12-31 | −21.99% | −22.66 pp |
| Q3 2018 | 2018-09-30 | 33.35% | +10.04 pp |
| Q2 2018 | 2018-06-30 | 23.96% | −3.62 pp |
| Q1 2018 | 2018-03-31 | 35.08% | +8.91 pp |
| Q4 2017 | 2017-12-31 | 0.67% | −19.80 pp |
| Q3 2017 | 2017-09-30 | 23.32% | −1.53 pp |
| Q2 2017 | 2017-06-30 | 27.58% | +2.62 pp |
| Q1 2017 | 2017-03-31 | 26.17% | +3.44 pp |
| Q4 2016 | 2016-12-31 | 20.47% | −3.24 pp |
| Q3 2016 | 2016-09-30 | 24.84% | +4.00 pp |
| Q2 2016 | 2016-06-30 | 24.95% | +0.00 pp |
| Q1 2016 | 2016-03-31 | 22.73% | +2.45 pp |
| Q4 2015 | 2015-12-31 | 23.70% | — |
| Q3 2015 | 2015-09-30 | 20.84% | — |
| Q2 2015 | 2015-06-30 | 24.95% | — |
| Q1 2015 | 2015-03-31 | 20.28% | — |
AbbVie net profit margin trends
Over the last five fiscal years, AbbVie's net profit margin decreased from 10.08% to 6.91%, a change of −3.17 percentage points. The latest reported quarter, Q2 2026, shows 21.27%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...